Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Education Session Reviews Current Management of Early-Stage NSCLC, Offers Glimpse of Future Advances
29 septembra, 2020 8:31 pmJune 3, 2017 Approximately 15% of all patients with non–small cell lung cancer (NSCLC) present with disease in early...
KARCINÓM PĽÚC NA ASCO 2017
29 septembra, 2020 8:31 pmÚvod Konferencia ASCO 2017 (v ďalšom texte iba ASCO) priniesla tento rok v oblasti karcinómu pľúc celý rad nových poznatkov a pre mňa...
A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC)
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Prostate) Cancer Abstract number: 5002 Citation: J Clin Oncol 35,...
Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 5502 Citation: J Clin Oncol 35,...
Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4500 Citation: J Clin Oncol 35,...
Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC)
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4501 Citation: J Clin Oncol 35,...
KEYNOTE-045: Pembrolizumab Maintains Overall Survival Benefit in Urothelial Cancer
29 septembra, 2020 8:30 pmJune 5, 2017 The PD-L1 inhibitor pembrolizumab continued to demonstrate an overall survival (OS) benefit compared with chemotherapy among...
Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B)
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4510 Citation: J Clin Oncol 35,...
DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC)
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4509 Citation: J Clin Oncol 35,...
Genomics May Provide New Insight Into Bladder Cancer Treatments
29 septembra, 2020 8:30 pmJune 4, 2017 In patients with upper tract urothelial carcinoma (UC) or who have early onset bladder cancer, screening...